Science
CME credits: 0.25 Valid until: 09-12-2021 Claim your CME credit at https://reachmd.com/programs/cme/clinical-and-practical-advances-management-hiv/12020/ Some two and a half decades since FDA approval of non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the management of HIV, newer versions continue to play an important therapeutic role in combination regimens. New NNRTIs are causing a stir because they can be paired with other high barrier to resistance agents. They also bring with them some other advantages associated with food intake and a possible neutral impact on lipids and weight gain. But an even more intriguing role may be on the horizon when NNRTIs are combined with emergent nucleoside reverse transcriptase translocation inhibitors (NRTTIs). Join us as Dr. David Wohl and Dr. Sorana Segal-Maurer take a close look at the who, what, when, and why of non-nucleoside reverse transcriptase inhibitors and their place in the current and future management of HIV.